Growth curves of NSCLC PDX models grouped by histology

Specificity of SGN-B6A in vitro cytotoxicity

A, h2A2 shows comparable binding to human and cynomolgus monkey integrin beta-6; B, Binding of h2A2 and SGN-B6A to human alpha-v/beta-6

H-Scores for integrin beta-6 across different cancer types

Antitumor activity in cell line-derived xenograft models

Legends for all supplementary figures in a single word file

Pharmacokinetic parameters of SGN-B6A in cynomolgus monkeys

Tumor and normal tissue mRNA levels of integrin beta-6 (ITGB6)

Cell lines used in the characterization of SGN-B6A

Evaluation of SGN-B6A effector function

Pharmacokinetics of 6 mg/kg SGN-B6A in cynomolgus monkeys as assessed by total antibody ELISA (Tab) and antibody-conjugated MMAE (acMMAE, determined by quantitative mass spectrometry)

2A2 antibody exhibits minimal blocking of integrin beta-6 binding to the latency-associated peptide (LAP) of tissue growth factor beta (TGF-β).

Correlation of integrin beta-6 expression as assessed by RNA Seq or IHC in Champions NSCLC models

Pharmacokinetics of 6 mg/kg SGN-B6A in cynomolgus monkeys as assessed by total antibody ELISA (Tab) and antibody-conjugated MMAE (acMMAE, determined by quantitative mass spectrometry)

Table S1, Table S2, Table S3, Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7

Supplemental data Figure 3 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

Supplemental data Figure 2 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

Supplemental data Figure 4 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70